Institution experience of FOLFIRINOX chemotherapy in advanced pancreatic cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter Y. Haddadin
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors Y. Haddadin1, R. Herbertson1, A. Webb1, E. Selvadurai1, A. Robinson1, I. Cornah2
  • 1Sussex Cancer Centre, Brighton, United Kingdom, /
  • 2East Sussex Healthcare NHS Trust, Eastbourne, United Kingdom, /

Abstract

Combination chemotherapy with FOLFIRINOX is widely recognised as the most active combination chemotherapy regimen for advanced pancreatic cancer, but is a tough and toxic regimen with many side effects and potential for hospital admissions. There is a key focus on time away from hospital and quality of life in this patient group where time is short, palliation is the priority and cure not possible. We therefore audited our practice of patients receiving this regimen over a 2 year period with particular focus on admissions.